Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

14 Nov 2019

Abstract excerpt

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden in MPN patients, underscoring the need for improved therapeutic strategies. Members of the PIM family of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Galectins and Cancer Biology
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31725895
DOI: 10.1182/bloodadvances.2019000260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNPMID 31725895Read ↗

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Semantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.